An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)
Phase of Trial: Phase IV
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Ixazomib (Primary) ; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms TOURMALINE MM-6
- Sponsors Takeda Oncology
- 06 Nov 2019 According to a Takeda media release, as of 1 April 2019, 55 patients had been enrolled at 16 sites in this study.
- 06 Nov 2019 Results published in the Takeda Media Release
- 06 Nov 2019 According to a Takeda media release, data from this trial will be presented at the 61st American Society of Hematology (ASH) Annual Meeting on December 7-10, 2019 in Orlando, FL.